Natural killer cell therapy with standard treatment for advanced nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study tests whether adding natural killer (NK) cells, which are immune cells that can attack cancer, to the usual chemotherapy and radiation treatment helps people with advanced nasopharyngeal cancer. It aims to improve treatment outcomes for patients with high-risk disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer that is stage III, IVA, or IVB, which means it is advanced or has spread to nearby lymph nodes.
- You are able to receive the standard chemotherapy and radiation treatment (called chemoradiotherapy).
- You have a positive test for the Epstein-Barr virus (EBV) in your blood at the time of diagnosis.
- Your blood counts and kidney and liver function are within acceptable limits.
- You are generally active and able to take care of yourself (ECOG performance status 0 or 1).
- You do not have an autoimmune disease or a weakened immune system, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to treat nasopharyngeal cancer that has spread, using a special type of radiation plus an immunotherapy drug. It is for people who cannot or choose not to have chemotherapy, and it aims to control the cancer while keeping side effects manageable.
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
This trial tests a new cell therapy called KSD-101 for nasopharyngeal cancer that has not responded to standard treatments. The therapy is injected into your lymph nodes and works by boosting your immune system to fight the cancer.
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This trial studies whether adding a PD-1 antibody (an immunotherapy) to standard chemoradiation can better control recurrent nasopharyngeal cancer that can’t be removed with surgery. If you qualify, you’d receive the study treatment and be closely monitored for side effects and cancer response.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.